MONTRÉAL, Nov. 7, 2024 /CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval ...

2024 /CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid cl... In-depth analysis showing robust Diamyd® treatment effects across ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

CEO Dev Kurdikar said the decision may “come as a surprise” as Embecta just received FDA clearance for a patch pump, but the company “did not intend to do a full market launch of this product.” ...

Embecta announced today that it discontinued its insulin patch pump program and plans to initiate a restructuring plan.

Kurdikar, CEO of Embecta (EMBC) said, “As our stand-up work nears completion and following an in-depth review of our portfolio ...

"They are challenged to do this relying solely on insulin, which is extremely difficult and is the principal therapy for people with T1D." An estimated 1.7 million adult Americans have T1D ...

Nov 7(Reuters) - Insulet (PODD.O), opens new tab raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps. Shares of the medical device maker ...